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Abstract
Introduction:  C-reactive  protein  (CRP)  and  Bedside  Index  for  Severity  in  Acute  Pancreatitis
(BISAP) have  been  used  in  early  risk  assessment  of  patients  with  AP.
Objectives:  We  evaluated  prognostic  accuracy  of  CRP  at  24  hours  after  hospital  admission
(CRP24) for  in-hospital  mortality  (IM)  in  AP  individually  and  with  BISAP.
Materials  and  Methods:  This  retrospective  cohort  study  included  134  patients  with  AP
from a  Portuguese  hospital  in  2009--2010.  Prognostic  accuracy  assessment  used  area  under
receiver--operating  characteristic  curve  (AUC),  continuous  net  reclassiﬁcation  improvement
(NRI), and  integrated  discrimination  improvement  (IDI).
Results:  Thirteen  percent  of  patients  had  severe  AP,  26%  developed  pancreatic  necrosis,  and  7%
died during  index  hospital  stay.  AUCs  for  CRP24  and  BISAP  individually  were  0.80  (95%  conﬁdence
interval  (CI)  0.65--0.95)  and  0.77  (95%  CI  0.59--0.95),  respectively.  No  patients  with  CRP24
<60 mg/l  died  (P  =  0.027;  negative  predictive  value  100%  (95%  CI  92.3--100%)).  AUC  for  BISAP
plus CRP24  was  0.81  (95%  CI  0.65--0.97).  Change  in  NRInonevents (42.4%;  95%  CI,  24.9--59.9%)
resulted in  positive  overall  NRI  (31.3%;  95%  CI,  −36.4%  to  98.9%),  but  IDInonevents was  negligible
(0.004;  95%  CI,  −0.007  to  0.014).Abbreviations: AP, acute pancreatitis; AUC, area under receiver--operating curve; BISAP, Bedside Index for Severity in Acute Pancreatitis;
ECT, contrast enhanced computed tomography; CI, conﬁdence interval; CRP, C-reactive protein; CRP24, C-reactive protein at 24 hours after
ospital admission; IDI, integrated discrimination improvement; IM, in-hospital mortality; NRI, continuous net reclassiﬁcation improvement;
R, odds ratio; SAP, severe acute pancreatitis; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.
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Conclusions:  CRP24  revealed  good  prognostic  accuracy  for  IM  in  AP;  its  main  role  may  be  the
selection  of  lowest  risk  patients.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Valor  Prognóstico  da  Proteína-C  Reativa  às  24  Horas  após  a  Admissão  Hospitalar  na
Pancreatite  Aguda:  Um  Estudo  Coorte  Retrospetivo
Resumo
Introduc¸ão: A  proteína-C  reativa  (CRP)  e  o  Bedside  Index  for  Severity  in  Acute  Pancreatitis
(BISAP) têm  sido  usados  na  avaliac¸ão  de  risco  precoce  de  doentes  com  pancreatite  aguda  (AP).
Objectivos:  Nós  avaliámos  o  valor  prognóstico  da  CRP  às  24  horas  após  a  admissão  hospitalar
(CRP24) na  mortalidade  intrahospitalar  (IM)  na  AP,  individualmente  e  com  o  BISAP.
Materiais  e  Métodos:  Este  estudo  coorte  retrospetivo  incluiu  134  doentes  com  AP  de  um  hos-
pital português  em  2009--2010.  A  acuidade  prognóstica  foi  avaliada  usando  a  área  debaixo  da
receiver-operating  characteristic  curve  (AUC),  o  continuous  net  reclassiﬁcation  improvement
(NRI), e  o  integrated  discrimination  improvement  (IDI).
Resultados:  Treze  por  cento  dos  doentes  tiveram  AP  grave,  26%  desenvolveram  necrose  pan-
creática, e  7%  morreram  durante  a  hospitalizac¸ão  índice.  As  AUCs  da  CRP24  e  do  BISAP
individualmente  foram  0,80  (intervalo  de  conﬁanc¸a  (IC)  95%,  0,65--0,95)  e  0,77  (IC  95%,
0,59--0,95),  respectivamente.  Nenhum  doente  com  CRP24  <60  mg/l  morreu  (P  =  0,027;  valor
predictivo  negativo  100%  (IC  95%,  92,3--100%)).  A  AUC  para  o  BISAP  mais  a  CRP24  foi  0,81  (IC
95%, 0,65--0,97).  A  mudanc¸a  no  NRI-não-eventos  (42,4%;  IC  95%,  24,9--59,9%)  resultou  num  NRI-
total positivo  (31,3%;  IC  95%,  −36,4  a  98,9%),  mas  num  IDI-não-eventos  negligenciável  (0,004;
IC 95%,  −0,007  a  0,014).
Conclusões:  A  CRP24  revelou  um  valor  prognóstico  bom  para  a  mortalidade  intrahospitalar  na
AP; o  seu  papel  principal  poderá  ser  a  selecc¸ão  dos  doentes  de  menor  risco.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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1. Introduction
The  incidence  of  acute  pancreatitis  (AP)  seems  to  be
increasing  in  several  countries.1,2 Most  cases  of  disease
follow  a  course  without  complications,  but  about  20%  of
patients  develop  severe  AP  (SAP).3 The  overall  mortality  is
2.1--7.8%,  but  SAP  leads  to  prolonged  hospitalization  and
higher  mortality.4,5
The  early  risk  assessment  of  patients  with  AP  by  accurate
and  reliable  methods  is  necessary  to  improve  clinical  out-
comes  and  reduce  costs  of  treatment.  Several  tools  for  the
early  risk  assessment  of  these  patients  have  been  developed;
they  include  single  biochemical  markers,  imaging  methods,
and  complex  scoring  systems.6
C-reactive  protein  (CRP)  is  an  acute  phase  reactant  that
has  been  largely  used  in  the  early  risk  assessment  of  patients
with  AP.  Among  single  biochemical  markers,  CRP  remains  the
most  useful  in  predicting  SAP,  especially  due  to  its  accuracy
and  accessibility.6,7 Despite  these  advantages,  its  prognostic
accuracy  has  been  validated  for  measurements  no  sooner
than  36  hours  after  hospital  admission.8,9 In  this  regard,
some  other  tools  for  earlier  risk  assessment  of  patients  with
AP,  as  Bedside  Index  for  Severity  in  AP  (BISAP),  might  be
more  useful.10
BISAP  has  been  validated  as  an  accurate  and  reliable
scoring  system  for  early  identiﬁcation  of  patients  with
T
t
(P  at  risk  for  in-hospital  mortality  (IM).10--12 It  comprises
he  assessment  of  5  clinical  variables  in  the  ﬁrst  24  hours
fter  hospital  admission:  Blood  urea  nitrogen  greater  than
5  mg/dl;  presence  of  impaired  mental  status  on  clinical
valuation;  presence  of  systemic  inﬂammatory  response
yndrome;  age  greater  than  60  years;  presence  of  pleural
ffusion  on  clinical  or  radiological  evaluation.  The  index
nal  score  is  calculated  by  adding  one  point  per  each  vari-
ble  present  (out  of  5  points).  According  to  this  scoring
ystem,  IM  increases  progressively  with  its  ﬁnal  score,  being
--20%  for  a  ﬁnal  score  equal  or  greater  than  3  points.10
In  this  study,  we  hypothesized  that  CRP  measured  at
4  hours  after  hospital  admission  (CRP24)  may  have  rele-
ant  prognostic  value  for  IM  in  AP  and  this  may  add  to  the
ne  from  BISAP.  Accordingly,  we  aimed  to  determine  CRP24
ndividual  prognostic  accuracy  for  IM  in  AP  and  identify  a
linically  signiﬁcant  cutoff  point;  additionally,  we  sought  to
uantify  the  combined  prognostic  accuracy  for  IM  in  AP  of
RP24  and  BISAP.
.  Materials and Methodshe  reporting  of  this  study  followed  the  Strengthening
he  Reporting  of  Observational  Studies  in  Epidemiology
STROBE)  statement.13 The  local  Health  Research  Ethics
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oard  approved  this  study  and  the  requirement  for  individual
nformed  consent  was  waived.
.1.  Design,  setting,  participants,  and  data
ollection
his  was  a  single  center  retrospective  cohort  study  which
ncluded  initially  all  patients  consecutively  admitted  to
he  emergency  department  of  a  Portuguese  general  dis-
rict  hospital  (Hospital  Professor  Doutor  Fernando  Fonseca,
madora)  with  AP  between  January  2009  and  December
010.  Of  this  set,  patients  with  incomplete  data  on  CRP24,
ISAP  score,  or  in-hospital  ﬁnal  vital  status  were  excluded.
Patients  were  identiﬁed  from  the  hospital’s  diagnostics
edicated  computerized  database.  Demographic  and  clini-
al  data  were  collected  by  3  investigators  from  a  variety  of
ources  including  patients’  charts  (manual  and  electronic),
aboratory  reports,  and  radiology  reports.
.2.  Operational  deﬁnitions
he  diagnosis  of  AP  was  made  if  2  of  the  following  3  fea-
ures  were  present:  (i)  Abdominal  pain  suggestive  of  AP;
ii)  serum  amylase  and/or  lipase  activity  at  least  3  times
reater  than  the  upper  limit  of  normal;  and  (iii)  charac-
eristic  ﬁndings  of  AP  on  transabdominal  ultrasonography
r  on  contrast-enhanced  computed  tomography  (CECT).14
espite  these  criteria,  all  patients  in  whom  the  minimum
-fold  hyperamylasemia  was  proved  to  be  from  other  cause,
ather  than  AP,  were  excluded.
Patients  were  classiﬁed  as  SAP  if  organ  failure  was
resent  for  more  than  48  hours.  In  accordance  to  the  Mar-
hall  Scoring  System,  organ  failure  includes  at  least  one  of
he  following  features:  (i)  Respiratory  failure,  deﬁned  as
O2/FiO2  ≤300  mmHg;  (ii)  renal  failure,  deﬁned  as  serum
reatinine  level  ≥1.9  mg/dl;  and  (iii)  shock,  deﬁned  as  sys-
olic  blood  pressure  <90  mmHg  and  unresponsive  to  ﬂuid
herapy.14
As  a  local  complication,  PNec  was  diagnosed  by  CECT
hen  there  was  lack  of  enhancement  of  pancreatic
arenchyma  after  contrast  infusion.14
For  each  patient,  all  CRP  determinations  obtained  during
he  ﬁrst  24  hours  after  hospital  admission  were  collected  and
nly  the  greatest  level  of  those  was  considered  for  analysis.
hese  CRP  determinations  were  obtained  using  the  standard
echnique  at  the  hospital’s  laboratory  (Dimension  Vista  Sys-
em,  Flex  reagent  cartridge,  Siemens  Healthcare  Diagnostics
roducts,  Germany)  and  expressed  in  mg/l.
BISAP  score  was  determined  according  to  what  has  been
reviously  published.10
.3.  Primary  exposures  and  primary  outcome
rimary  exposures  were  CRP  level  and  BISAP  score  in  the
rst  24  hours  after  hospital  admission.  Primary  outcome
as  IM,  which  referred  to  death  occurring  from  AP  or  its
omplications  (inﬂammatory,  septic,  morphological  or  oth-
rs)  during  index  hospital  stay.
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.4.  Statistical  analysis
ategorical  variables  were  presented  as  frequencies  and
ercentages  and  continuous  variables  as  median  and  inter-
uartile  range  (percentile  25--percentile  75)  or  range
minimum--maximum).  Missing  data  were  not  replaced  or
stimated.
Univariable  analysis  used  nonparametric  tests  (Chi-
quare,  Fisher’s  Exact,  Mann--Whitney  U)  due  to  the
xistence  of  outliers  and  skewed  distributions.  Logistic
egression  models  were  used  to  evaluate  the  prognostic
ccuracy  of  CRP24  and  BISAP  for  IM  with  odds  ratios  (ORs)
eing  calculated  after  cross-validation.  Discriminative  abil-
ty  was  assessed  by  the  area  under  the  receiver--operating
haracteristic  curve  (AUC)15 and  comparison  between  AUCs
as  made  using  the  method  described  by  DeLong  et  al.16
o  compensate  for  possible  shortcomings  of  AUC  analysis
n  quantifying  the  added  value  of  a  biomarker  to  an  exist-
ng  test,  continuous  net  reclassiﬁcation  improvement  (NRI)
nd  integrated  discrimination  improvement  (IDI)  parameters
ere  also  calculated.17,18
All  statistical  tests  were  two-sided  and  P  <0.05  was  con-
idered  statistically  signiﬁcant.  All  analyses  were  performed
ith  IBM  SPSS  Statistics,  Version  19.0  (IBM  Corp.,  North  Cas-
le,  New  York,  USA)  and  Stata/IC  12.0  (Statacorp.  LP,  College
tation,  TX,  USA).
. Results
.1.  Patients’  characteristics
 total  of  299  patients  were  initially  included.  Of  this  set,
nly  134  patients  (44.8%)  had  complete  data  on  CRP24,
ISAP,  and  in-hospital  ﬁnal  vital  status  and  were  subse-
uently  considered.
Median  age  was  64  years  (range,  13--96  years),  with  80
en  (59.7%).  Biliary  lithiasis  was  the  most  frequent  iden-
iﬁable  cause  of  AP  with  59  patients  (44.0%).  Of  a  total
f  70  patients  (52.2%)  with  complete  data  on  organ  fail-
re  parameters,  9  (12.9%)  developed  organ  failure  for  more
han  48  hours  and  were  classiﬁed  as  having  SAP.  CECT  was
erformed  in  91  patients  (67.9%)  and  in  24  of  those  (26.4%)
ancreatic  necrosis  was  found.  Median  day  for  CECT  per-
ormance  was  the  fourth  day  of  hospital  stay  (range,  1--26
ays).  From  the  70  patients  with  Marshall  score  evaluation,
1  (72.9%)  underwent  CECT;  from  the  9  patients  with  SAP,
 (44.4%)  were  diagnosed  with  pancreatic  necrosis.  Median
ength  of  hospital  stay  was  9  days  (range,  1--80  days).  Nine
atients  (6.7%)  died  during  index  hospital  stay.  Median  time
o  death  was  15  days  (range,  1--60  days).
.2.  CRP24  prognostic  accuracy  for  IM
edian  overall  CRP24  level  was  104.4  (inter-quartile  range,
9.2--191.2  mg/l)  and  its  distribution  by  IM  status  is  shown  in
ig.  1.  Median  CRP24  level  was  higher  in  patients  who  died
uring  index  hospital  stay  (197.2  vs.  100.2,  p  =  0.003).  CRP24
nivariable  OR  for  IM  was  1.11  (95%  CI,  1.04--1.17)  and  corre-
ponding  AUC  was  0.80  (95%  CI,  0.65--0.95).  Analysis  of  the
oordinate  points  of  the  receiver--operating  characteristic
urve  showed  that,  from  the  46  patients  with  a  CRP24  level
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Fig.  3  Receiver--operating  characteristic  curve  (ROC)  of  Bed-
side Index  for  Severity  in  Acute  Pancreatitis  (BISAP;  full  line)
and BISAP  plus  C-reactive  protein  at  24  hours  after  hospital
admission  (CRP24;  dashed  line)  prognostic  accuracy  for  in-
hospital  mortality  (IM).  BISAP  area  under  ROC  (AUC)  of  0.77
(
0
3
f
A
w
1
0
w24 hours  after  hospital  admission  (CRP24)  level  and  in-hospital
mortality  (IM)  status.
lower  than  60  mg/l,  none  died  (p  =  0.027).  Additionally,  from
the  9  patients  with  SAP,  only  one  (11.1%)  had  a  CRP24  level
lower  than  60  mg/l.  This  CRP24  cutoff  point  yielded  the  fol-
lowing  sensitivity,  speciﬁcity,  negative  predictive  value,  and
positive  predictive  value  for  IM:  100%  (95%  CI,  66.4--100%),
36.8%  (95%  CI,  28.4--45.9%),  100%  (95%  CI,  92.3--100%),  and
10.0%  (95%  CI,  4.8--18.5%),  respectively.
3.3.  BISAP  prognostic  accuracy  for  IM
The  distribution  of  patients  by  BISAP  categories  is  shown
in  Fig.  2.  Twenty-three  patients  (17%)  had  a  BISAP  score
equal  or  greater  than  3.  BISAP  univariable  OR  for  IM  was
2.27  (95%  CI,  1.37--3.77)  and  corresponding  AUC  was  0.77
(95%  CI,  0.59--0.95).
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Fig.  2  Distribution  of  patients  by  Bedside  Index  for  Severity
in Acute  Pancreatitis  (BISAP)  categories.
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i95% CI,  0.59--0.95)  and  BISAP  plus  CRP24  AUC  of  0.81  (95%  CI,
.65--0.97).
.4.  BISAP  plus  CRP24  model  prognostic  accuracy
or IM
fter  cross-validation,  BISAP  plus  CRP24  model  ORs  for  IM
ere  1.77  (95%  CI,  1.05--3.00)  for  BISAP  and  1.09  (95%  CI,
.02--1.16)  for  CRP24;  corresponding  AUC  was  0.81  (95%  CI,
.65--0.97).  AUCs  of  BISAP  alone  and  BISAP  plus  CRP24  model
ere  not  signiﬁcantly  different  (Fig.  3: P  =  0.62).
Statistics  of  BISAP  prognostic  accuracy  for  IM  improve-
ent  with  the  addition  of  CRP24  are  summarized  in  Table  1.
he  overall  reclassiﬁcation  of  patients  (NRI)  was  mainly  due
o  the  reclassiﬁcation  of  survivors  (non-events),  as  absolute
RInonevents was  greater  than  NRIevents.  In  fact,  the  NRInonevents
howed  a  signiﬁcant  change  (42.4%;  95%  CI,  24.9--59.9%)
hich  resulted  in  a  positive  overall  NRI  (31.3%;  95%  CI,  −36.4
o  98.9%),  but  the  IDInonevents was  negligible,  with  a  95%  CI
traddling  zero  (0.004;  95%  CI,  −0.007  to  0.014).  This  means
hat  the  addition  of  CRP24  to  BISAP  reduced  the  calculated
isk  of  IM  in  about  42%  of  patients  who  survived,  albeit  the
verall  effect  was  not  statistically  signiﬁcant.
.  Discussion
n  this  study,  we  found  that  CRP24  may  be  a  useful  biochem-
cal  marker  for  the  early  risk  assessment  of  patients  with
P.
CPR24  showed  good  individual  prognostic  accuracy  for  IM
n  AP.  Moreover,  the  evaluation  of  a  possible  cutoff  point
ith  clinical  relevance  revealed  that  60  mg/l  warranted  a
egative  predictive  value  of  100%,  meaning  that  patients
ith  AP  and  a  CRP24  level  lower  than  that  cutoff  point
ere  not  at  risk  of  dying  from  AP  or  its  complications  dur-
ng  the  following  hospital  stay.  The  low  prevalence  of  IM  in
202  
Table  1  Statistics  of  BISAP’s  prognostic  accuracy  for  in-
hospital  mortality  in  acute  pancreatitis  improvement  with
the addition  of  CRP24.
Statistics  Coefﬁcient  (95%  CI)
AUC
BISAP  0.77  (0.59--0.95)
BISAP +  CRP24  0.81  (0.65--0.97)
NRI (%)
NRIevents −11.1  (−76.4  to  54.2)
NRInonevents 42.4  (24.9--59.9)
NRIa 31.3  (−36.4  to  98.9)
IDI
IDIevents 0.029  (−0.115  to  0.173)
IDInonevents 0.004  (−0.007  to  0.014)
IDIb 0.033  (−0.112  to  0.177)
CI, conﬁdence interval; AUC, area under receiver--operating
curve; BISAP, Bedside Index for Severity in Acute Pancreatitis;
CRP24, C-reactive protein at 24 hours after hospital admission;
NRI, continuous net reclassiﬁcation improvement; IDI, inte-
grated discrimination improvement; Events, patients that died;
Nonevents, patients that survived.
a NRI equals NRIevents plus NRInonevents.
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population-based study. Gut. 2008;57:1698--703.IDI equals IDIevents plus IDInonevents.
his  population-based  study  may  have  precluded  the  deter-
ination  of  a  cutoff  point  with  a  high  positive  predictive
alue.19
Adding  CPR24  to  BISAP  may  have  represented  an  improve-
ent  in  prognostic  accuracy  for  IM  in  AP;  in  this  regard,
he  real  gain  may  have  been  due  to  the  reclassiﬁcation  of
atients  at  low  risk  to  die  from  AP  or  its  complications  dur-
ng  index  hospital  stay.  Despite  these  observed  tendencies,
tatistical  signiﬁcance  was  not  achieved.
Overall,  this  study  emphasizes  the  role  of  CRP24  in  the
arly  risk  assessment  of  patients  with  AP  individually  and  in
ombination  with  BISAP.  These  results  underline  the  possi-
le  advantages  of  combining  simple  and  accessible  tools  for
linicians  to  perform  a  more  reliable  early  risk  assessment
f  patients  with  AP,  as  it  has  been  outlined  elsewhere20;
his  may  be  done  not  only  by  selecting  patients  at  high
isk  for  complications,  but  also  by  identifying  those  within
he  low  risk  subgroup  that  most  probably  will  not  develop
omplications.  This  approach  may  help  speciﬁc  institutional
olicies  on  AP  by  improving  efﬁciency  in  patient  manage-
ent  and  resources  utilization.
There  were  some  methodological  limitations  to  this
tudy.  First,  this  was  a  retrospective  analysis  of  prospec-
ively  collected  data  from  a  single  center  and  may  have  been
rone  to  selection  bias  and  limited  generalization.  Second,
issing  CRP24  determinations,  which  made  the  ﬁnal  sample
ize  smaller,  might  have  impacted  negatively  the  ﬁnal  pro-
nostic  accuracy  results  for  the  BISAP  plus  CRP24  model.  The
ethodological  strengths  of  this  study  were  mainly  the  com-
unity  based  and  consecutive  admission  of  patients  and  the
dditional  use  of  NRI  and  IDI  to  assess  the  prognostic  perfor-
ance  of  BISAP  plus  CRP24  model.  In  the  future,  prospective
nd  properly  powered  studies  should  address  CRP24  pro-
nostic  accuracy  in  AP  and  the  possibility  of  combining  it
1F.S.  Cardoso  et  al.
ith  BISAP  or  other  early  risk  assessment  tools  available  for
atients  with  AP.
In  conclusion,  there  seems  to  be  a  role  for  CRP24  in  the
arly  risk  assessment  of  patients  with  AP,  especially  by  iden-
ifying  lowest  risk  patients.
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